CN111227045A - Application of dairy product in promoting growth of length of mammal - Google Patents

Application of dairy product in promoting growth of length of mammal Download PDF

Info

Publication number
CN111227045A
CN111227045A CN202010104314.1A CN202010104314A CN111227045A CN 111227045 A CN111227045 A CN 111227045A CN 202010104314 A CN202010104314 A CN 202010104314A CN 111227045 A CN111227045 A CN 111227045A
Authority
CN
China
Prior art keywords
bifidobacterium
powder
dairy product
weight
raw material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010104314.1A
Other languages
Chinese (zh)
Other versions
CN111227045B (en
Inventor
李玉珍
石羽杰
刘彪
李威
肖竞舟
叶文慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Yili Industrial Group Co Ltd
Original Assignee
Inner Mongolia Yili Industrial Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Yili Industrial Group Co Ltd filed Critical Inner Mongolia Yili Industrial Group Co Ltd
Publication of CN111227045A publication Critical patent/CN111227045A/en
Application granted granted Critical
Publication of CN111227045B publication Critical patent/CN111227045B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention belongs to the field of food or medicine, and particularly discloses application of a dairy product in preparing food or medicine for improving or promoting growth of the body of a mammal, wherein the dairy product comprises a protein providing raw material, a fat providing raw material and bifidobacteria, the protein providing raw material is selected from animal milk, milk powder, whey protein powder and β -casein, the protein providing raw material at least contains a-lactalbumin and β -casein, the fat providing raw material at least contains palmitic acid glyceride, the palmitic acid glyceride contains more than 15% of Sn-2 palmitic acid glyceride by weight calculated according to palmitic acid, and the bifidobacteria is selected from at least one of bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum and bifidobacterium infantis.

Description

Application of dairy product in promoting growth of length of mammal
Technical Field
The invention belongs to the field of food or medicine, and particularly relates to an application of a dairy product in promoting the growth of the body length of a mammal.
Background
The growth of human body is not a constant velocity process, and the growth rate of human body varies from birth to adult. Taking Chinese as an example, the body length of a born infant is about 50 cm, the body length increases about 11-12 cm in 3 months, increases about 12-13 cm in 3-12 months, continues to increase about 11-12 cm in 1-2 years, increases about 5-7 cm per year in 2 years to early puberty, and increases about 8-9 cm per year in adolescence. The fastest growing period of life is 2 years ago and adolescence. The critical period of increased length requires an adequate supply of nutrients. The research finds that: water with very low mineral content can lead to retarded bone density growth and retarded height growth of teenagers; in the 0 to 2 year old stage, protein restriction results in lower levels of insulin-like growth factor 1(IGF-1) in healthy children, both energy restriction (50% reduction in intake) and protein restriction (reduction of protein from 1.0g/kg to 0.66g/kg body weight per day) lead to a significant reduction in nitrogen balance in children, a decrease in IGF-1 concentration and in the concentration of specific IGF-binding proteins, affecting body function, body growth and body composition. There is a need for a method of promoting growth in the length of an infant or teenager.
The fat of breast milk provides 45-60% of energy for early growth of infants, more than 98% of the fat of breast milk is triglyceride, and the esterification positions of different fatty acids and the glycerol in the breast milk are different, wherein unsaturated fatty acids such as linoleic acid and α -linolenic acid in the breast milk are more than 1 position and 3 position of the triglyceride, long-chain saturated fatty acids such as palmitic acid in the breast milk are mainly positioned at 2 position, so that the formed triglyceride of palmitic acid is called Sn-2 triglyceride palmitate, in the digestive tract, the fat hydrolase of the stomach of infants mainly acts on ester bonds at 1 position and 3 position of the triglyceride, therefore, the unsaturated fatty acids are firstly free and then degraded and absorbed together with Sn-2 monoglyceride in duodenum.
Breast milk is rich in a-lactalbumin, a protein rich in essential amino acids, which is digested to produce a variety of biologically active polypeptides. Researches show that the a-lactalbumin digestion product can inhibit pathogenic bacteria such as escherichia coli, pneumococcus, staphylococcus aureus, candida and the like in vitro.
β -Casein is casein molecule with highest content in breast milk, and polypeptide fragment obtained by digestion has effect in inhibiting growth of harmful bacteria.
Probiotics are an important component of the gut microbiota. The definitions of probiotics by the world Food and Agriculture Organization (FAO) and the World Health Organization (WHO) are: by ingesting a suitable amount of live bacteria, the live bacteria can exert an effective effect on the health of the consumer. The bifidobacterium is one of probiotics, and the currently common bifidobacterium strains comprise bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum, bifidobacterium infantis and the like, and a plurality of novel strains.
Disclosure of Invention
The present invention provides the use of a milk product for improving or promoting the growth of the length of a mammal, such as an infant or adolescent.
The invention relates to the use of a dairy product for the preparation of a food or a medicament for improving or promoting the growth of the body length of a mammal;
the dairy product, comprising: a protein-providing material, a fat-providing material and bifidobacteria; wherein the content of the first and second substances,
the raw material for providing protein is selected from animal milk, milk powder, whey protein powder and β -casein, and the raw material for providing protein at least contains a-whey protein and β -casein;
the fat-providing raw material contains at least palmitic acid glyceride, and the palmitic acid glyceride contains 15% or more (for example, 18% or more, 20% or more, 15% to 98%, 15% to 90%, 20% to 80%, 20% to 95%, 30%, 40%, 50%, 60%, 70%) by weight of Sn-2 palmitic acid glyceride;
the Bifidobacterium is selected from at least one of Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium adolescentis, Bifidobacterium bifidum and Bifidobacterium infantis.
In some embodiments of the present invention, the protein-providing raw material is 200 to 1600 parts by weight, for example, 400 parts by weight, 700 parts by weight, 800 parts by weight, 900 parts by weight, 1000 parts by weight, 1200 parts by weight, 1500 parts by weight; the fat-providing raw material is 70 to 500 parts by weight, for example, 100 parts by weight, 200 parts by weight, 300 parts by weight, and 400 parts by weight.
In some embodiments of the invention, the weight ratio of the a-lactalbumin, β -casein and Sn-2 glyceryl palmitate in the dairy product is (1-10): (1-10): 1-10), such as 1 (1-2): 1-2), 1 (1-5): 1-5), (1-4): 1 (1-5), 1 (1-7): 1-7), 1 (1-6): 1-6), 1:1.32:1.2, 1:1:1, 1:3:3, 1:5:5, 1:8: 8.
In some embodiments of the invention, the dairy product has a viable count of bifidobacteria of 10 per gram of β -casein6～1011CFU, e.g. 107CFU、108CFU、109CFU、1010CFU。
In some embodiments of the invention, the bifidobacteria in the dairy product are selected from the group consisting of bifidobacterium BB12 and bifidobacterium HN 019.
In some embodiments of the invention, the ratio of viable count of bifidobacterium BB12 to bifidobacterium HN019 in the dairy product is (1:100) to (100:1), for example 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 20:1, 10:1, 5:1, 1:5, 1:8, 1:10, 1:14, 1:17, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1: 90.
In some embodiments of the invention, the milk product is prepared from a fat-providing raw material selected from the group consisting of OPO structural fat, vegetable fat and animal fat.
In some embodiments of the invention, the vegetable oil is selected from the group consisting of sunflower oil, corn oil, rapeseed oil, and soybean oil.
In some embodiments of the invention, the fat-providing feedstock comprises OPO structural fat, sunflower seed oil, corn oil, soybean oil, and optionally rapeseed oil.
In some embodiments of the invention, the dairy product further comprises a carbohydrate-providing raw material.
In some embodiments of the invention, the carbohydrate is a carbohydrate commonly used in the art.
In some embodiments of the invention, the carbohydrate-providing source is selected from lactose, sucrose, glucose, starch and dextrin, preferably lactose.
In some embodiments of the present invention, the carbohydrate-providing raw material is 100 to 600 parts by weight, for example, 100 parts by weight, 150 parts by weight, 200 parts by weight, 250 parts by weight, 300 parts by weight, 350 parts by weight, 400 parts by weight, 450 parts by weight, 500 parts by weight, 560 parts by weight.
In some embodiments of the invention, the dairy product further comprises at least one selected from the group consisting of vitamins, minerals, dietary fiber, DHA, ARA, phospholipids, and choline chloride.
In some embodiments of the invention, the viable count of bifidobacteria per hundred grams of dairy product is 103～1015CFU, e.g. 104CFU、105CFU、107CFU、108CFU、109CFU、1010CFU、1011CFU、1012CFU、1013CFU、1014CFU。
In some embodiments of the invention, the dairy product comprises the following raw materials:
Figure BDA0002387976320000041
Figure BDA0002387976320000051
the dairy product contains Bifidobacterium BB12 and Bifidobacterium HN019, wherein the viable count of Bifidobacterium BB12 is 10 per gram of β -casein6～1011CFU (e.g. 10)7CFU、108CFU、109CFU、1010CFU), viable count of Bifidobacterium HN019 is 10 per gram of β -casein6～1011CFU (e.g. 10)7CFU、108CFU、109CFU、1010CFU)。
In some embodiments of the invention, the dairy product further comprises vitamins and/or minerals.
In some embodiments of the invention, the vitamin is contained in an amount of 1-500 mg, such as 10mg, 20mg, 50mg, 100mg, 120mg, 150mg, per hundred grams of dairy product.
In some embodiments of the invention, the dairy product contains 10-3000 mg of minerals per hundred grams, such as 20mg, 40mg, 60mg, 100mg, 200mg, 300mg, 400mg, 500mg, 700mg, 800mg, 1000mg, 1500mg, 2000mg, 2500mg, 3000 mg.
In some embodiments of the invention, the vitamin is selected from the group consisting of vitamin A, vitamin C, vitamin D, vitamin E, vitamin K1Vitamin B1Vitamin B2Vitamin B6Vitamin B12Niacin, folic acid, pantothenic acid, and biotin.
In some embodiments of the invention, the mineral is selected from the group consisting of sodium, potassium, copper, magnesium, iron, zinc, calcium, phosphorus, iodine, selenium, and derivatives thereof.
Some embodiments of the invention include one or more of the following (a) to (d):
(a) the animal milk and milk powder are respectively derived from at least one mammal selected from cow, sheep, horse, deer and camel;
(b) the whey protein powder is selected from desalted whey protein powder, undesalted whey protein powder and a-whey protein powder;
preferably, the weight of the desalted whey protein powder is 1-20 times, such as 2, 5, 7, 9, 10, 12, 14, 15, 17, 19 times of the weight of the undesalted whey protein powder;
preferably, the weight of the undesalted whey protein powder is 0.5-40 times of the weight of the a-whey protein powder, such as 1, 2, 5, 10, 20, 25, 30, 35 and 40 times;
(c) the dietary fiber is selected from fructo-oligosaccharide and galacto-oligosaccharide;
preferably, the weight ratio of the fructo-oligosaccharide to the galacto-oligosaccharide is 1 (1-6), such as 1:2, 1:3, 1:4, 1: 5;
(d) the phospholipid is soybean phospholipid.
In some embodiments of the invention, the animal milk is selected from the group consisting of raw milk, whole milk, low fat milk, and skim milk.
In some embodiments of the invention, the milk powder is selected from the group consisting of whole milk powder, low-fat milk powder, and skim milk powder, preferably whole milk powder and skim milk powder;
preferably, the weight ratio of the whole milk powder and the skim milk powder is (0.1-12) to 1, such as 0.2:1, 0.3:1, 0.5:1, 1:1, 2:1, 3:1, 4:1, 5:1, 7:1, 10:1, 11: 1.
In some embodiments of the invention, the dairy product is prepared by:
(1-1) mixing the raw materials except for bifidobacterium, DHA and ARA to obtain a mixture;
(2-1) homogenizing the mixture to obtain a homogeneous material;
(3) sterilizing the homogenized material to obtain a sterilized material;
(4) drying the sterilized material to obtain powder;
(5) and dry-mixing the powder, the bifidobacterium, the DHA and the ARA to obtain the dairy product.
Some embodiments of the invention include one or more of the following 1) to 11):
1) the method also comprises a step (1-2) between the steps (1-1) and (2-1): filtering the mixture to remove impurities, and using the obtained filtered material for homogenization treatment in the step (2-1);
2) in the step (2-1), the temperature of the homogenization treatment is 50 ℃ or higher;
3) in the step (2-1), the pressure of the homogenization treatment is 120bar or more;
4) a step (2-2) is further included between the steps (2-1) and (3): concentrating the homogenized material, and using the obtained concentrate for sterilization treatment in the step (3);
preferably, the dry matter content of the concentrate is between 40% and 60% by weight;
5) in the step (3), the temperature of the sterilization treatment is more than 80 ℃;
6) in the step (3), the time of sterilization treatment is 10-60 seconds;
7) in the step (4), before drying treatment, filtering and removing impurities from the sterilized materials;
8) in the step (4), the sterilized material is firstly introduced into a spray drying tower for primary drying, and then the material obtained by the primary drying is introduced into a fluidized bed for secondary drying to obtain powder;
preferably, the air inlet temperature of the spray drying tower is 150-200 ℃;
preferably, the air exhaust temperature of the spray drying tower is 80-120 ℃;
preferably, the negative pressure of the spray drying tower is-10 to-2 mmWG;
preferably, the sterilizing material is introduced into the spray drying tower by means of a high-pressure pump;
more preferably, the pressure of the high-pressure pump is 140-250 bar;
9) in the step (5), the dry mixing temperature is 20-35 ℃;
10) in the step (5), dry mixing is carried out through a fluidized bed;
11) the method further comprises step (6): the dairy product is screened.
In some embodiments of the invention, the dairy product comprises:
Figure BDA0002387976320000071
Figure BDA0002387976320000081
Figure BDA0002387976320000091
the dairy product also comprises Bifidobacterium BB12 and Bifidobacterium HN019, wherein the viable count of the Bifidobacterium BB12 is 10 per gram of β -casein6～1011CFU (e.g. 10)7CFU、108CFU、109CFU、1010CFU), viable count of Bifidobacterium HN019 is 10 per gram of β -casein6～1011CFU (e.g. 10)7CFU、108CFU、109CFU、1010CFU) containing 1 to 500mg (e.g. 10mg, 20mg, 50mg, 100mg, 120mg, 150mg) of vitamins and 10 to 3000mg (e.g. 20mg, 40mg, 60mg, 100mg, 200mg, 300mg, 400mg, 500mg, 700mg, 800mg, 1000mg, 1500mg, 2000mg, 2500mg, 3000mg) of minerals per hundred grams of dairy product.
In some embodiments of the invention, the mammal is a human, preferably an infant or adolescent.
In the invention, the dairy product is selected from at least one of sterilized milk, reconstituted milk, yoghourt, yogurt, milk powder, formula milk powder, condensed milk, cheese, casein, whey powder, milk fat and milk-containing beverage, and is preferably (infant) formula milk powder.
In the present invention, unless otherwise specified, wherein:
the term "glyceryl palmitate" refers to fatty acid glycerides having at least one palmitic acid attached to a glyceryl moiety, and may be selected from monoesters, diesters and triesters, wherein other fatty acid moieties may also be attached to the glyceryl moieties of the diesters, triesters.
The term "Sn-2 palmitic acid" refers to palmitic acid attached to the Sn-2 position on a glyceryl portion of a fat.
The term "Sn-2 glyceryl palmitate" refers to fatty acid glycerides with palmitic acid attached to the Sn-2 position of the glyceryl moiety, and may be selected from the group consisting of Sn-2 monoglycerides, Sn-2 diglycerides and Sn-2 triglycerides; wherein, any fatty acid can be connected to the Sn-1 position and/or the Sn-3 position on the glyceryl in the Sn-2 palmitic acid diglyceride and the Sn-2 palmitic acid triglyceride, and the fatty acid comprises, but is not limited to, palmitic acid, butyric acid, caproic acid, caprylic acid, capric acid, stearic acid, lauric acid, myristic acid, arachic acid, myristoleic acid, palmitoleic acid, rapeseed oleic acid, linoleic acid, linolenic acid and the like.
The term "a-lactalbumin" is a protein extracted from milk, has the characteristics of high nutritional value, easy digestion and absorption, various active ingredients and the like, and is one of high-quality protein supplements for human bodies.
The term "β -casein" is a phosphorylated protein synthesized by mammary acinar epithelial cells and is widely found in the milk of mammals (cows, yaks, goats, horses, rabbits, etc.) and humans.
The term "OPO structure fat" is actually a structured fat, and the molecular structure of breast milk fat is simulated by an enzymatic lipid exchange technology, so that the proportion of 2-position palmitic acid is up to more than 40 percent and is closer to the level of breast milk.
The invention has the following beneficial effects:
the dairy product of the invention can improve or promote the growth of the body of infants or teenagers.
Detailed Description
Embodiments of the present invention will now be described more fully hereinafter with reference to the accompanying examples, in which some, but not all embodiments of the invention are shown. The following description of at least one exemplary embodiment is merely illustrative in nature and is in no way intended to limit the invention, its application, or uses. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
(1) Mixing whole milk powder, skimmed milk powder, lactose, whey protein powder (purity 80 wt.%), desalted whey powder (purity 12 wt.%), a-whey protein powder (purity 77 wt.%), OPO structure fat, high oleic sunflower seed oil, corn oil, soybean oil, galacto-oligosaccharide syrup (purity 57 wt.%), fructo-oligosaccharide (chicory source), β -casein, soybean phospholipid, choline chloride and compound nutrients (the components are shown in Table 1-2) uniformly according to the formula in Table 1-1, and removing impurities from the mixed material by using a filter screen to obtain a material after impurity removal;
(2) homogenizing the material after removing impurities at a temperature above 55 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) concentrating the standby materials to obtain a concentrate with the dry matter content of 48-52%;
(4) sterilizing the concentrate at above 83 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) preheating the sterilized material in a thick milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) further drying the powder material by a first-stage fluidized bed to obtain dry powder;
(7) dry mixing the dry powder, DHA, ARA and two kinds of bifidobacterium powder at 25-30 ℃ through a secondary fluidized bed to obtain mixed powder;
(8) and (3) sieving the mixed powder by using a vibrating screen to obtain the formula milk powder 1 with uniform particles, and filling nitrogen for packaging.
The formula 1 contains 22% of Sn-2 palmitic acid glyceride in the palmitic acid glyceride, the weight ratio of a-lactalbumin, β -casein to Sn-2 palmitic acid glyceride is 2:1:2.4, the formula contains 1.6 wt% of a-lactalbumin, and the sum of the viable count of two bifidobacteria is 2 multiplied by 10 in terms of a-lactalbumin per gram7CFU。
Table 1-1 formulation of example 1
Figure BDA0002387976320000111
Figure BDA0002387976320000121
Table 1-2 ingredients contained in the Complex Nutrients
Figure BDA0002387976320000122
Figure BDA0002387976320000131
Example 2
(1) Mixing whole milk powder, skimmed milk powder, lactose, whey protein powder (purity 34 wt.%), desalted whey powder (purity 12 wt.%), a-whey protein powder (purity 77 wt.%), OPO structure fat, high-oleic sunflower seed oil, corn oil, soybean oil, galacto-oligosaccharide syrup (purity 57 wt.%), fructo-oligosaccharide (chicory source), β -casein, soybean phospholipid, choline chloride and compound nutrients (the components are shown in Table 2-2) uniformly according to the formula in Table 2-1, and removing impurities from the mixed material by using a filter screen to obtain a material after impurity removal;
(2) homogenizing the material after removing impurities at a temperature above 55 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) concentrating the standby materials to obtain a concentrate with the dry matter content of 48-52%;
(4) sterilizing the concentrate at above 83 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) preheating the sterilized material in a thick milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) further drying the powder material by a first-stage fluidized bed to obtain dry powder;
(7) dry mixing the dry powder, DHA, ARA and two kinds of bifidobacterium powder at 25-30 ℃ through a secondary fluidized bed to obtain mixed powder;
(8) and (3) sieving the mixed powder by using a vibrating screen to obtain the formula milk powder 2 with uniform particles, and filling nitrogen for packaging.
The formula 2 contains 22% of Sn-2 palmitic acid glyceride in the palmitic acid glyceride, the weight ratio of a-lactalbumin, β -casein to Sn-2 palmitic acid glyceride is 2.5:1:4, the formula contains 1 wt% of a-lactalbumin, and the sum of the viable count of two bifidobacteria is 3 x 10 in terms of each gram of a-lactalbumin7CFU。
Table 2-1 formulation of example 2
Figure BDA0002387976320000141
Figure BDA0002387976320000151
TABLE 2-2 ingredients contained in the Complex Nutrients
Figure BDA0002387976320000152
Figure BDA0002387976320000161
Comparative example
(1) Mixing whole milk powder, skimmed milk powder, lactose, whey protein powder (purity 80 wt.%), desalted whey powder (purity 12 wt.%), OPO structure fat, high oleic sunflower seed oil, corn oil, soybean oil, rapeseed oil, galacto-oligosaccharide syrup (purity 57 wt.%), fructo oligosaccharide (from chicory), soybean phospholipid, choline chloride and compound nutrients (the components are shown in table 3-2) uniformly according to the formula in table 3-1, and removing impurities by using a mixed material filter screen to obtain an impurity-removed material;
(2) homogenizing the material after removing impurities at a temperature above 55 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) concentrating the standby materials to obtain a concentrate with the dry matter content of 48-52%;
(4) sterilizing the concentrate at above 83 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) preheating the sterilized material in a thick milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) further drying the powder material by a first-stage fluidized bed to obtain dry powder;
(7) dry mixing the dry powder, DHA and ARA at 25-30 ℃ by a secondary fluidized bed to obtain mixed powder;
(8) and (3) sieving the mixed powder by using a vibrating screen to obtain formula milk powder A with uniform particles, and filling nitrogen for packaging.
In formula A, the palmitic acid glyceride contains 12.5% by weight of Sn-2 palmitic acid glyceride, based on the weight of palmitic acid, and is substantially free of a-lactalbumin, β -casein, and bifidobacteria.
TABLE 3-1 formulation of comparative example
Components Dosage (kg)
Whole milk powder 230
Defatted milk powder 100
Lactose 305
Whey protein powder (purity 80 wt.%) 50
Desalted whey powder (purity 12 wt.%) 170
OPO structural fat 100
High oleic sunflower oil 40
Corn oil 30
Soybean oil 70
Rapeseed oil 60
Galacto-oligosaccharide syrup (purity 57 wt.%) and 45
fructo-oligosaccharide (chicory source) 10
Soybean lecithin 1.4
Choline chloride 0.9
DHA 6
ARA 6
Compound nutrient 13.4
TABLE 3-2 ingredients contained in the Complex Nutrients
Figure BDA0002387976320000171
Figure BDA0002387976320000181
Clinical test method and test results
The feeding effect of the formula of example 1 and the formula of the comparative example were compared in a random control design.
1. Grouping of subjects:
infants in need of inclusion were screened by recruiting screening questionnaires by pediatricians or trained researchers. Written informed consent was obtained from the mother prior to study entry.
1.1 inclusion criteria
And (3) full-term infants: the gestational week is more than or equal to 37 weeks;
birth weight: 2.5kg-4 kg;
normal pregnancy, delivered baby (including cesarean);
healthy, Apgar score > 7 after birth for 5-10 minutes;
age: < 15 days.
1.2 exclusion criteria
Infants with any of the following characteristics were excluded:
congenital malformations or chromosomal disorders detected at birth and of clinical significance;
patients with disease requiring mechanical ventilation or medication within one week after birth (infant jaundice patients who do not include blue light therapy);
those who affect feeding or metabolism due to suspected or unknown metabolic factors or due to physical defects;
twins or multiple births.
1.3 Experimental groups
Infants of 0-6 months old and full-term are selected as study objects, the infants are fed with the infant formula milk powder, the feeding amount of the infant formula milk powder of 1-15 days old is more than or equal to 250ml/d, the infants with the dry starting prognosis milk powder feeding rate of more than 80% are randomly divided into a test group (fed with the formula milk powder of example 1) and a control group (fed with the formula milk powder of a comparative example). The number of people in each group is not less than 5.
2. Intervention study method
Baseline (postnatal day 15) surveys and sample collections were conducted on enrolled infants, followed by continuous feeding for 6 months, during which time the subject was followed by visits by the project investigator at 4, 6, 8, 16, and 24 weeks after the start of feeding. The growth and development of the infants are investigated.
3. Results of clinical experiments
The Z scoring method is the most common method for evaluating the nutritional status of the group of children before school age at present, and because the influences of factors such as age, sex, height and the like are eliminated, the evaluation result is more accurate and objective. The weight and the height are selected as two evaluation indexes, the numerical value of the standard reference population adopts the international standard or WHO standard designated by the national health statistic center (NCHS), and the Z score of the age-related Height (HAZ) of each child is calculated respectively. The Z score is calculated using the standard formula: z-score (measured value-median value of standard reference population)/standard deviation of standard reference population. The Z score of HAZ is less than 2, and is regarded as the basis for judging low weight, hypoevolutism and emaciation of children, and the Z score of HAZ is more than 2, and is regarded as overweight, overweight and obese.
The Z-scores of age-related Height (HAZ) at baseline, week 4, week 6, week 8, week 16 and week 24 for the infants of the test and control groups are shown in table 4. Where each data is represented in the median (25 th percentile, 75 th percentile). The Z-scores for each group of infants are ranked from low to high, "median" represents the Z-score for infants ranked in the middle position, "25 th percentile" represents the Z-score for infants ranked in (cohort × 25%) position, and "75 th percentile" represents the Z-score for infants ranked in (cohort × 75%) position. The p-value represents the p-value of the significance test between the control and test groups.
Pure artificial feeding means that the feeding amount of the artificial milk powder exceeds 80 percent of the daily food intake.
TABLE 4Z score (median (25 th percentile, 75 th percentile) for pure artificially fed infant age Height (HAZ)
Test set Control group
HAZ 0.2(-0.78,1.18) -0.2(-0.91,0.62)
p value 0.027
From the above results, it can be seen that the infants in the test group and the infants in the control group have a significant difference in their growth (α ═ 0.05 level) under the pure artificial feeding condition, and the growth of the infants in the test group is significantly faster than that of the infants in the control group.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.

Claims (10)

1. Use of a dairy product for the manufacture of a food product or medicament for improving or promoting growth in the length of a mammal;
the dairy product comprises: a protein-providing material, a fat-providing material and bifidobacteria; wherein the content of the first and second substances,
the raw material for providing protein is selected from animal milk, milk powder, whey protein powder and β -casein, and the raw material for providing protein at least contains a-whey protein and β -casein;
the raw material for providing fat at least contains palmitic acid glyceride, and the palmitic acid glyceride contains 15% by weight or more of Sn-2 palmitic acid glyceride;
the Bifidobacterium is selected from at least one of Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium adolescentis, Bifidobacterium bifidum and Bifidobacterium infantis;
preferably, the protein-providing raw material is 200 to 1600 parts by weight, and the fat-providing raw material is 70 to 500 parts by weight.
2. Use according to claim 1, wherein the dairy product is characterized by one or more of the following (a) to (C):
(A) the weight ratio of the a-lactalbumin, the β -casein and the Sn-2 glyceryl palmitate is (1-10) to (1-10);
(B) the viable count of the bifidobacteria is 10 according to the weight of β -casein per gram6～1011CFU；
(C) The Bifidobacterium is selected from Bifidobacterium BB12 and Bifidobacterium HN 019;
preferably, the ratio of viable count of Bifidobacterium BB12 to Bifidobacterium HN019 is (1:100) to (100: 1).
3. The use according to claim 1, wherein in the dairy product, the raw material providing fat is selected from the group consisting of OPO structural fat, vegetable fat and animal fat;
preferably, the vegetable oil is selected from sunflower oil, corn oil, rapeseed oil and soybean oil.
4. Use according to claim 1, wherein the dairy product further comprises a carbohydrate providing raw material;
preferably, the carbohydrate-providing raw material is selected from lactose, sucrose, glucose, starch and dextrin;
preferably, the carbohydrate-providing raw material is 100 to 600 parts by weight.
5. Use according to claim 1, wherein the dairy product further comprises at least one selected from the group consisting of vitamins, minerals, dietary fiber, DHA, ARA, phospholipids and choline chloride.
6. Use according to claim 1, wherein the dairy product comprises:
Figure FDA0002387976310000021
the dairy product contains Bifidobacterium BB12 and Bifidobacterium HN019, wherein the viable count of Bifidobacterium BB12 is 10 per gram of β -casein6～1011The viable count of CFU and bifidobacterium HN019 is 10 according to the weight of β -casein per gram6～1011CFU。
7. Use according to claim 6, wherein the milk product further comprises vitamins and/or minerals;
preferably, the milk product contains 1-500 mg of vitamins per hundred grams of milk product;
preferably, the milk product contains 10-3000 mg of minerals per hundred grams of milk product.
8. Use according to any one of claims 1 to 7, wherein, among the dairy products, one or more of the following (a) to (d) are characterized:
(a) the animal milk and milk powder are respectively derived from at least one mammal selected from cow, sheep, horse, deer and camel;
(b) the whey protein powder is selected from desalted whey protein powder, undesalted whey protein powder and a-whey protein powder;
preferably, the weight of the desalted whey protein powder is 1-20 times that of the undesalted whey protein powder;
preferably, the weight of the undesalted whey protein powder is 0.5-40 times of that of the a-whey protein powder;
(c) the dietary fiber is selected from fructo-oligosaccharide and galacto-oligosaccharide;
preferably, the weight ratio of the fructo-oligosaccharide to the galacto-oligosaccharide is 1 (1-6);
(d) the phospholipid is soybean phospholipid.
9. Use according to claim 6 or 7, wherein the dairy product is prepared by:
(1-1) mixing the raw materials except for bifidobacterium, DHA and ARA to obtain a mixture;
(2-1) homogenizing the mixture to obtain a homogeneous material;
(3) sterilizing the homogenized material to obtain a sterilized material;
(4) drying the sterilized material to obtain powder;
(5) dry-mixing the powder, the bifidobacteria, the DHA and the ARA to obtain a dairy product;
preferably, it is characterized by one or more of the following 1) to 11):
1) the method also comprises a step (1-2) between the steps (1-1) and (2-1): filtering the mixture to remove impurities, and using the obtained filtered material for homogenization treatment in the step (2-1);
2) in the step (2-1), the temperature of the homogenization treatment is 50 ℃ or higher;
3) in the step (2-1), the pressure of the homogenization treatment is 120bar or more;
4) a step (2-2) is further included between the steps (2-1) and (3): concentrating the homogenized material, and using the obtained concentrate for sterilization treatment in the step (3);
preferably, the dry matter content of the concentrate is between 40% and 60% by weight;
5) in the step (3), the temperature of the sterilization treatment is more than 80 ℃;
6) in the step (3), the time of sterilization treatment is 10-60 seconds;
7) in the step (4), before drying treatment, filtering and removing impurities from the sterilized materials;
8) in the step (4), the sterilized material is firstly introduced into a spray drying tower for primary drying, and then the material obtained by the primary drying is introduced into a fluidized bed for secondary drying to obtain powder;
preferably, the air inlet temperature of the spray drying tower is 150-200 ℃;
preferably, the air exhaust temperature of the spray drying tower is 80-120 ℃;
preferably, the negative pressure of the spray drying tower is-10 to-2 mmWG;
preferably, the sterilizing material is introduced into the spray drying tower by means of a high-pressure pump;
more preferably, the pressure of the high-pressure pump is 140-250 bar;
9) in the step (5), the dry mixing temperature is 20-35 ℃;
10) in the step (5), dry mixing is carried out through a fluidized bed;
11) the method further comprises step (6): the dairy product is screened.
10. Use according to any one of claims 1 to 7, wherein the mammal is a human, preferably an infant or adolescent.
CN202010104314.1A 2019-11-20 2020-02-20 Application of dairy product in promoting growth of length of mammal Active CN111227045B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911142713 2019-11-20
CN2019111427130 2019-11-20

Publications (2)

Publication Number Publication Date
CN111227045A true CN111227045A (en) 2020-06-05
CN111227045B CN111227045B (en) 2023-04-14

Family

ID=70862730

Family Applications (8)

Application Number Title Priority Date Filing Date
CN201911345399.6A Pending CN112823646A (en) 2019-11-20 2019-12-24 Composition, food or drug and use thereof
CN202010104301.4A Active CN111227044B (en) 2019-11-20 2020-02-20 Dairy product, preparation method and medical application thereof
CN202010104314.1A Active CN111227045B (en) 2019-11-20 2020-02-20 Application of dairy product in promoting growth of length of mammal
CN202010104302.9A Active CN111248287B (en) 2019-11-20 2020-02-20 Application of dairy product in improving neurodevelopment
CN202010135666.3A Active CN112823667B (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic
CN202310545216.5A Pending CN116584653A (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic
CN202010135335.XA Active CN112823647B (en) 2019-11-20 2020-03-02 Application of composition in improving or promoting growth of infant
CN202010135640.9A Active CN112823648B (en) 2019-11-20 2020-03-02 Composition, food or medicine and application thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201911345399.6A Pending CN112823646A (en) 2019-11-20 2019-12-24 Composition, food or drug and use thereof
CN202010104301.4A Active CN111227044B (en) 2019-11-20 2020-02-20 Dairy product, preparation method and medical application thereof

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN202010104302.9A Active CN111248287B (en) 2019-11-20 2020-02-20 Application of dairy product in improving neurodevelopment
CN202010135666.3A Active CN112823667B (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic
CN202310545216.5A Pending CN116584653A (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic
CN202010135335.XA Active CN112823647B (en) 2019-11-20 2020-03-02 Application of composition in improving or promoting growth of infant
CN202010135640.9A Active CN112823648B (en) 2019-11-20 2020-03-02 Composition, food or medicine and application thereof

Country Status (1)

Country Link
CN (8) CN112823646A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114145346A (en) * 2021-11-29 2022-03-08 内蒙古伊利实业集团股份有限公司 Food composition, application of food composition in improving or promoting magnesium absorption and infant formula milk powder
CN114223721A (en) * 2020-09-09 2022-03-25 内蒙古伊利实业集团股份有限公司 Application of palmitic acid glyceride in improving or promoting protein absorption of infants

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823646A (en) * 2019-11-20 2021-05-21 内蒙古伊利实业集团股份有限公司 Composition, food or drug and use thereof
CN114287478A (en) * 2021-11-23 2022-04-08 临夏燎原乳业产业研究院有限公司 Formula yak milk powder for promoting height increase and brain development of children and preparation method thereof
CN114145458A (en) * 2021-11-29 2022-03-08 内蒙古伊利实业集团股份有限公司 Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body
CN115669945B (en) * 2022-10-24 2024-03-08 上海艾斯顿医疗科技有限公司 Liposome-coated polypeptide with neurotrophic effect, and preparation method and application thereof
CN116369527A (en) * 2023-03-09 2023-07-04 江南大学 Bifidobacterium breve capable of regulating bone development and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150237902A1 (en) * 2012-09-11 2015-08-27 Nucitec, S.A. De C.V. Infant formula for optimal growth, gastrointestinal protection and immunological protection of infants
AU2018101868A4 (en) * 2017-12-01 2019-01-17 Noumi Ip Pty Ltd Milk Substitute Compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010953A2 (en) * 2011-11-10 2017-12-05 Nestec Sa infant formulas and their uses
CN102524421B (en) * 2011-12-31 2013-05-22 黑龙江省完达山乳业股份有限公司 Novel acid-base balance infant formula milk powder and preparation method thereof
MX2012010487A (en) * 2012-09-11 2014-03-26 Nucitec Sa De Cv Composition of nutrients and bioactive substances which promote growth and reduce intolerance and side effects in premature infants.
CN103053694A (en) * 2013-02-18 2013-04-24 杨凌圣妃乳业有限公司 Infant goat milk powder simulating components of breast milk and preparation method thereof
CN104351356A (en) * 2014-11-25 2015-02-18 澳优乳业（中国）有限公司 Novel fourth-generation infant formula and preparation method thereof
CN105767213A (en) * 2014-12-26 2016-07-20 丰益(上海)生物技术研发中心有限公司 Grease composition and preparation method thereof
CN106259952B (en) * 2015-06-01 2019-01-15 内蒙古伊利实业集团股份有限公司 1-3 years old baby formulas milk powder and preparation method thereof containing nucleotide and dietary fiber
CN106259953B (en) * 2015-06-01 2019-01-29 内蒙古伊利实业集团股份有限公司 Breast milk 0-12 month babies ' formula milk powder containing nucleotide and preparation method thereof
CN105053217A (en) * 2015-09-14 2015-11-18 海普诺凯营养品有限公司 Infant formula ewe milk powder and production method thereof
CN107668211B (en) * 2017-11-13 2021-08-10 海普诺凯营养品有限公司 Infant formula goat milk powder for enhancing immune function and preparation method thereof
CN110063372A (en) * 2018-01-23 2019-07-30 天津澳斯乳业有限公司 A kind of infant formula goat milk powder and its production method
CN108013143A (en) * 2018-02-05 2018-05-11 高培（广州）乳业有限公司 One kind strengthens the formula milk of 12 ~ 36 months infant's gastrointestinal functions
CN108157512A (en) * 2018-02-05 2018-06-15 高培（广州）乳业有限公司 A kind of formula milk for strengthening 6 ~ 12 months infant's gastrointestinal functions
CN112823646A (en) * 2019-11-20 2021-05-21 内蒙古伊利实业集团股份有限公司 Composition, food or drug and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150237902A1 (en) * 2012-09-11 2015-08-27 Nucitec, S.A. De C.V. Infant formula for optimal growth, gastrointestinal protection and immunological protection of infants
AU2018101868A4 (en) * 2017-12-01 2019-01-17 Noumi Ip Pty Ltd Milk Substitute Compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TORMO R等: "Fecal fat and nitrogen excretion in infants fed a formula with 40% of palmitic acid in the beta position of triglyceride", 《CLINICAL NUTRITION》 *
史瑞雪等: "益生菌在婴幼儿食品中的应用研究现状", 《现代食品》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114223721A (en) * 2020-09-09 2022-03-25 内蒙古伊利实业集团股份有限公司 Application of palmitic acid glyceride in improving or promoting protein absorption of infants
CN114145346A (en) * 2021-11-29 2022-03-08 内蒙古伊利实业集团股份有限公司 Food composition, application of food composition in improving or promoting magnesium absorption and infant formula milk powder

Also Published As

Publication number Publication date
CN116584653A (en) 2023-08-15
CN111248287B (en) 2023-04-14
CN111227044A (en) 2020-06-05
CN111227045B (en) 2023-04-14
CN111227044B (en) 2023-05-16
CN112823667B (en) 2023-06-02
CN112823646A (en) 2021-05-21
CN112823647B (en) 2023-04-07
CN111248287A (en) 2020-06-09
CN112823647A (en) 2021-05-21
CN112823648A (en) 2021-05-21
CN112823648B (en) 2023-03-31
CN112823667A (en) 2021-05-21

Similar Documents

Publication Publication Date Title
CN111227045B (en) Application of dairy product in promoting growth of length of mammal
CN1838888B (en) Baby or second stage formula milk
US9144250B2 (en) Nutritional formulation for promoting catch-up growth
EP1976397B1 (en) Infant immunological formula
TW201028104A (en) Nutritional composition to promote healthy development and growth
CN108522655A (en) The baby milk and preparation method of micro functional active components in a kind of across-the-board regulation formula
US11606966B2 (en) Nutritional formula
JP2016505024A (en) Baby food composition containing bacteria that produce viable propionic acid
JP2016505024A5 (en)
RU2677924C2 (en) Fermented nutrition high in lactose with increased iron bioavailability
MX2013005943A (en) Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions.
EA011075B1 (en) Dry powdered milk formula
US20180360090A1 (en) Nutritional compositions and infant formulas to promote myelination in the brain
CN112535217A (en) Maternal emulsified hypoallergenic fresh and alive infant formula milk and preparation method thereof
AU2016376167A1 (en) Nutritional compositions and infant formulas to promote myelination in the brain
ES2857815T3 (en) Methods of use of fermented formula for infants
CN111227046B (en) Application of dairy product in improving infant intestinal SIgA level
Falcão et al. Infant Formulas: A Long Story
AU2016374162A1 (en) Nutritional compositions and infant formulas to promote myelination in the brain
CN114145458A (en) Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body
CN114145346A (en) Food composition, application of food composition in improving or promoting magnesium absorption and infant formula milk powder
TW201822640A (en) Compositions comprising maltotriose and methods of using same to inhibit damage caused by dehydration processes
CN114223721A (en) Application of palmitic acid glyceride in improving or promoting protein absorption of infants
US20240008520A1 (en) Nutritional Composition for Infants and/or Children and Methods for Making Same
BR112021004949A2 (en) nutritional compositions, their use in reducing metabolic stress and method for reducing metabolic stress

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant